$10.47
-0.58 (-5.25%)
USD · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where EIKN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
10 interventional
Held by 5 tracked-famous managers (Schonfeld Strategic Advisors LLC, MILLENNIUM MANAGEMENT LLC, POLEN CAPITAL MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC) · FINRA short interest 20.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.NCT06697301Progression Free Survival (PFS)Randomized · Quadruple-masked · Treatment | Phase 2/3 | Recruiting | Drug: EIK1001, Pembrolizumab (KEYTRUDA® ) | Advanced Melanoma | 740 | Dec 2035 | ≤ 3,421 d | 2026-05-08 |
| A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.NCT07365319Progression-free survival (PFS)Randomized · Quadruple-masked · Treatment | Phase 2/3 | Recruiting | Drug: EIK1001, Pembrolizumab (KEYTRUDA®), Placebo, Paclitaxel + Carboplatin, Nab-paclitaxel + Carboplatin, Pemetrexed + Cisplatin /Carboplatin | Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC | 750 | 2035-12-31 | in 3,421 d | 2026-08-19 |
| EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) TumorsNCT07262619Dose-Limiting Toxicity (DLT) - Part 1Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: EIK1005, pembrolizumab (KEYTRUDA® ) | Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer, Endometrial Cancer, Mismatch Repair Deficient or MSI-High Solid Tumors | 160 | Mar 2029 | ≤ 955 d | 2026-04-08 |
| A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.NCT06907043Number of Participants who experience a Dose-Limiting Toxicity (DLT)Open-label · Treatment | Phase 1/2 | Recruiting | Drug: EIK1004-001 (IMP1707-001) | Advanced Solid Tumors | 130 | Dec 2028 | ≤ 865 d | 2025-08-19 |
| A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid TumorsNCT06253130Number of subjects with adverse events, treatment emergent adverse events or serious adverse eventsOpen-label · Treatment | Phase 1/2 | Recruiting | Drug: IMP1734 | Advanced Solid Tumor | 156 | 2027-06-01 | in 286 d | 2026-06-15 |
| A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLCNCT06246110Percentage of participants with safety event during treatmentNon-randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: EIK1001, Pembrolizumab, Paclitaxel, Pemetrexed, Carboplatin | NSCLC | 70 | Dec 2026 | ≤ 134 d | 2026-05-28 |
| BDB001-102: Open Label Dose Escalation of BDB001 in Combination w AtezolizumabNCT04196530Safety and Tolerability: incidence of adverse events and any dose limiting toxicityNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: BDB001 (EIK1001), Atezolizumab | Tumor, Solid | 40 | 2024-07-31actual | — | 2025-11-12 |
| BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With PembrolizumabNCT03486301Safety and Tolerability: incidence of adverse events and any dose limiting toxicityNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: BDB001 (EIK1001), Pembrolizumab | Tumor, Solid | 87 | 2024-03-31actual | — | 2025-11-12 |
| Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsNCT04840394Safety and Tolerability: incidence of adverse events and any dose limiting toxicityNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: BDB018, Pembrolizumab | Tumor, Solid | 1 | 2024-03-31actual | — | 2025-11-12 |
| BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid TumorsNCT04819373Efficacy as measured by Objective Response RateOpen-label · Treatment | Phase 2 | Completed | Drug: BDB001 | Tumor, Solid | 1 | 2023-04-01actual | — | 2025-11-12 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19